Literature DB >> 8754806

Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.

M K Webster1, P Y D'Avis, S C Robertson, D J Donoghue.   

Abstract

Thanatophoric dysplasia type II (TDII) is a neonatal lethal skeletal dysplasia caused by a recurrent Lys-650-->Glu mutation within the highly conserved activation loop of the kinase domain of fibroblast growth factor receptor 3 (FGFR3). We demonstrate here that this mutation results in profound constitutive activation of the FGFR3 tyrosine kinase, approximately 100-fold above that of wild-type FGFR3. The mechanism of FGFR3 activation in TDII was probed by constructing various point mutations in the activation loop. Substitutions at position 650 indicated that not only Glu but also Asp and, to a lesser extent, Gln and Leu result in pronounced constitutive activation of FGFR3. Additional mutagenesis within the beta10-beta11 loop region (amino acids Tyr-647 to Leu-656) demonstrated that amino acid 650 is the only residue which can activate the receptor when changed to a Glu, indicating a specificity of position as well as charge for mutations which can give rise to kinase activation. Furthermore, when predicted sites of autophosphorylation at Tyr-647 and Tyr-648 were mutated to Phe, either singly or in combination, constitutive kinase activity was still observed in response to the Lys-650-->Glu mutation, although the effect of these mutations on downstream signalling was not investigated. Our data suggest that the molecular effect of the TDII activation loop mutation is to mimic the conformational changes that activate the tyrosine kinase domain, which are normally initiated by ligand binding and autophosphorylation. These results have broad implications for understanding the molecular basis of other human developmental syndromes that involve mutations in members of the FGFR family. Moreover, these findings are relevant to the study of kinase regulation and the design of activating mutations in related tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8754806      PMCID: PMC231404          DOI: 10.1128/MCB.16.8.4081

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  33 in total

1.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

Authors:  C I Bargmann; M C Hung; R A Weinberg
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

2.  Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction.

Authors:  M Mohammadi; I Dikic; A Sorokin; W H Burgess; M Jaye; J Schlessinger
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

Review 3.  Fibroblast-growth-factor receptor mutations in human skeletal disorders.

Authors:  M Muenke; U Schell
Journal:  Trends Genet       Date:  1995-08       Impact factor: 11.639

4.  Thanatophoric dwarfism.

Authors:  K Shah; R Astley; A H Cameron
Journal:  J Med Genet       Date:  1973-09       Impact factor: 6.318

5.  Histopathology and ultrastructure of cartilage in the chondrodystrophies.

Authors:  D L Rimoin
Journal:  Birth Defects Orig Artic Ser       Date:  1974

6.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

Authors:  H Nagata; A S Worobec; C K Oh; B A Chowdhury; S Tannenbaum; Y Suzuki; D D Metcalfe
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

7.  Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome.

Authors:  K M Neilson; R E Friesel
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

8.  Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose.

Authors:  L Ellis; E Clauser; D O Morgan; M Edery; R A Roth; W J Rutter
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

9.  Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice.

Authors:  J D Coffin; R Z Florkiewicz; J Neumann; T Mort-Hopkins; G W Dorn; P Lightfoot; R German; P N Howles; A Kier; B A O'Toole
Journal:  Mol Biol Cell       Date:  1995-12       Impact factor: 4.138

10.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.

Authors:  M K Webster; D J Donoghue
Journal:  EMBO J       Date:  1996-02-01       Impact factor: 11.598

View more
  51 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

2.  Unliganded fibroblast growth factor receptor 1 forms density-independent dimers.

Authors:  Laëtitia Comps-Agrar; Diana Ronai Dunshee; Dan L Eaton; Junichiro Sonoda
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

3.  Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.

Authors:  April N Meyer; Peggy Modaff; Clark G Wang; Elizabeth Wohler; Nara L Sobreira; Daniel J Donoghue; Richard M Pauli
Journal:  Am J Med Genet A       Date:  2020-12-02       Impact factor: 2.802

4.  Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain.

Authors:  M K Webster; D J Donoghue
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

5.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

Review 6.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

Review 7.  Advances in Skeletal Dysplasia Genetics.

Authors:  Krista A Geister; Sally A Camper
Journal:  Annu Rev Genomics Hum Genet       Date:  2015-04-22       Impact factor: 8.929

8.  Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor.

Authors:  Jinhua Wu; Wanqing Li; Barbara P Craddock; Kenneth W Foreman; Mark J Mulvihill; Qun-sheng Ji; W Todd Miller; Stevan R Hubbard
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

9.  Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.

Authors:  Jonathan R St-Germain; Paul Taylor; Jiefei Tong; Lily L Jin; Ana Nikolic; Ian I Stewart; Robert M Ewing; Moyez Dharsee; Zhihua Li; Suzanne Trudel; Michael F Moran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

10.  Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.

Authors:  Do-Hee Kim; Yeonui Kwak; Nam Doo Kim; Taebo Sim
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.